Preliminary Product Data

Early Steady findings: what 38 measured support sessions showed

We are publishing this early snapshot because product data is most useful when the method, denominator, uncertainty, and limitations are visible alongside the headline.

By Winnie Taiwo · Published Aug 25, 2026 · Preliminary, non-clinical product data
Measured-session signal
79%
of 38 measured Steady support sessions showed lower self-reported distress after the support flow than before it.
Measured sessions38 sessions with both a pre- and post-session distress measure
Outcome summarizedDirection of change in self-reported distress within the same session
Unit of analysisSession, not necessarily unique participant
Study designEarly observational product data; no control group or randomization
The headline, carefully stated

What the 79% number means

In this early snapshot, 79% of measured sessions ended with a lower self-reported distress measure than the session began with. We use that as a product signal: a reason to keep studying whether Steady's short support flow is useful in emotionally activated moments.

79% does not mean distress was reduced by 79%. It is the share of measured sessions that moved in a lower direction from pre-session to post-session. This snapshot does not report the average or median size of that change.
How the snapshot was measured

Pre/post self-report within a support session

Steady's Get Support experience is designed for short, in-the-moment regulation support. For this early analysis, a measured session is one in which a distress measure was available both before and after the support flow.

  1. A user begins a support session and reports their distress before the intervention flow.
  2. The user moves through the short Steady support experience.
  3. A post-session distress measure is captured.
  4. The pre- and post-session values are compared for direction of change.

This page reports the proportion of measured sessions in which the post-session value was lower than the pre-session value. It does not turn that within-session change into a diagnosis, clinical outcome, or claim of treatment effectiveness.

What we can say

What this early signal is useful for

What we cannot say

This is not clinical efficacy evidence

This snapshot can describeIt cannot establish
Within-session direction of self-reported distress changeThat Steady caused the change
What happened in these 38 measured sessionsHow every Steady user will respond
An early product signal worth testingClinical efficacy or treatment of a mental-health condition
Immediate pre/post experienceWhether any change lasts hours, days, or longer
Session-level observationsParticipant-level effectiveness if some people contributed more than one session
Why this matters: without a control condition, randomization, independent validation, and longer follow-up, other explanations for the observed change remain possible. People may improve with time, expectancy, attention, self-selection, or other factors unrelated to the product itself.
What we want to measure next

Moving from an early signal toward stronger evidence

As Steady grows, the next useful questions are not simply whether the 79% number gets larger. They are whether we can understand the signal more rigorously and whether it is meaningful over time.

Evidence behind the product

Product data and external research are different evidence layers

Steady uses evidence-informed breathing, grounding, stress-regulation, and behavior-change concepts. Research supporting those techniques can inform product design, but it does not automatically validate the Steady product itself. We keep those evidence layers separate.

Data note

How to cite or describe this finding

Preferred wording: “In an early Steady product-data snapshot of 38 measured support sessions, 79% showed lower self-reported distress after the support flow than before it.”

Avoid: “Steady reduces distress by 79%,” “Steady is 79% effective,” or language that treats this preliminary session-level signal as clinical efficacy.

Source: Steady internal product analytics. Preliminary, non-randomized, non-clinical product data. Published Aug 25, 2026.

Winnie Taiwo, founder of Steady
Co-Founder & CEO · Public health and data analytics background

See how Steady handles evidence

Read our standards for research interpretation, product data, citations, and clinical review.

Research Standards & Evidence